尿毒清颗粒联合厄贝沙坦治疗Ⅳ期糖尿病肾病的疗效观察.docxVIP

尿毒清颗粒联合厄贝沙坦治疗IV期糖尿病肾病的疗效观察 龚丽娜(广东省佛山市南海区第二人民医院肾内科 广东佛山528251) 【摘要】目的 探讨尿毒清颗粒联合厄贝沙坦对IV期糖尿病肾病(diabetic nephropathy, DN)患者的疗效。方法 将62例DNIV期患者随机分为厄贝沙坦 组(对照组，31例)和尿毒清联合厄贝沙坦组(治疗组，31例)。两组初始均服 用厄贝沙坦150mg/d,从第三周起可耐受则加量至300mg/d,不耐受者不变、减 量甚至退组。治疗组从开始联用尿毒清颗粒。疗程均为3个月。比较治疗前后两 组治疗效果及不良反应，统计每组厄贝沙坦的平均日用量及退组患者情况。结果 2组治疗后UAE、Scr、TC、TG、hs?CRP、FIB各指标均较治疗前有改善，治疗组 优于对照组(Plt;0.05)o对照组血钾升高较明显。治疗组1例退组，对照组4 例退组。治疗组厄贝沙坦平均用量为174mg/d,对照组为155mg/do结论 较单 用厄贝沙坦，尿毒清颗粒联合厄贝沙坦治疗DNIV期患者能更有效减少蛋白尿， 保护肾功能，更安全。 【关键词】尿毒清颗粒 厄贝沙坦 糖尿病肾病 疗效观察 【中图分类号】R453 【文献标识码】A 【文章编号】2095-1752 (2013) 13-0115-02 Clinical efficacy of Compound Niaoduqing particles and irbesartan in patients with stage IV diabetic nephropathy Gong Lina(Department of Nephrology, The Second Peoplersquo;s Hospital of Nanhai District, Foshan City, Guangdong Province, Foshan 528251, China) 【Abstract】Objective To explore the effect of combination of Niaoduqing particles and irbesartan in patients with stage IV diabetic nephropathy(DN). Methods 62 patients with DNIV were randomly divided into the Irbesatan group(control group, 31 cases) and Niaoduqing Irbesatan group (treatment group, 31 cases). The initial all groups taki ng irbesarta n 150mg/d, can be tolerated from the third week on ward the dose to 300mg/d. The intoleranee unchanged, reduce or even withdrawal group? The treatment group started associated with Niaoduqing particles. The course was 3 mon ths. Compare two groups before and after treatme nt therapeutic effects and adverse reactions, the average daily amount of each group of irbesartan and withdrawal patientsrsquo; condition. Results After treatment, UAE Scr TC、TG^ hs-CRP、FIB improved in both groups, the treatment group was super to control group(Plt;0.05)o Control group elevated serum potassium more obvious. There was 1 patient retreat group in the treatment group, and 4 patients in the control group. The average dose of irbesartan was 174mg/d in the treatment group, and 155mg/d in ano ther. Conclusion The combi nation of Niaodu qing parti